STAT+: AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Edison Scientific spun off from FutureHouse in late 2025 with $70 million in venture funding to commercialize AI agents for drug discovery.
- A top-10 drugmaker offered FutureHouse $30 million to use its AI agents, prompting CEO Sam Rodriques to initially think there was a misunderstanding.
- An AI head at another big pharma company called FutureHouse's agents "the Ferrari of agents," saying there was no point in building their own on top of OpenAI or Anthropic.
- FutureHouse was founded in 2023 by Sam Rodriques (formerly of the Francis Crick Institute's Applied Biotechnology Lab) and Andrew White (former University of Rochester chemical engineering professor) to give every scientist AI agents that could reason on their own.
- Per the article's headline, the team behind Metsera has tapped Edison Scientific to create new biotechs.
Why it matters: Edison's $70M raise and the Metsera partnership position its AI scientist agents as a commercial drug-discovery product—not a research project. Big pharma is willing to pay $30 million to license them rather than build comparable tools on top of OpenAI or Anthropic, which is the real competitive moat.
Ask SkimNews
